IBRX (ImmunityBio) Institutional Ownership: 16.98% (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBRX ImmunityBio Inc IBRX
60 GF Score
Price $8.40
GF Value $22.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ImmunityBio Institutional Ownership?

ImmunityBio IBRX +1.82% 60 Institutional Ownership is 16.98% as of Aug. 28, 2026. GuruFocus rates IBRX with a GF Score™ of 60/100 and a GF Value™ of $22.42 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ImmunityBio's institutional ownership is 16.98%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ImmunityBio's Insider Ownership is 0.41%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ImmunityBio's Float Percentage Of Total Shares Outstanding is 37.83%.

ImmunityBio Institutional Ownership Historical Data

* Premium members only.

The historical data trend for ImmunityBio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio Institutional Ownership Chart

ImmunityBio Historical Data

The historical data trend for ImmunityBio can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 8.00 8.40 9.74 10.04 10.16 10.72 10.96 11.02 12.08 12.48
IBRX
60GF Score
ImmunityBio Inc IBRX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmunityBio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 16.98% mean?
ImmunityBio (IBRX) has a Institutional Ownership of 16.98% as of Aug. 28, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ImmunityBio and its competitors.
Is ImmunityBio's Institutional Ownership too high?
ImmunityBio's current Institutional Ownership is 16.98%. Overall, ImmunityBio has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImmunityBio's Institutional Ownership compare to RYTM and PCVX?
ImmunityBio's Institutional Ownership of 16.98% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ImmunityBio and its competitors. ImmunityBio's current Institutional Ownership is 16.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmunityBio stock overvalued right now?
Based on GuruFocus' analysis, ImmunityBio (IBRX) is currently considered Possible Value Trap. The stock's GF Value™ is $22.42, compared to a current price of $8.40 — trading 62.6% below its estimated fair value. The current Institutional Ownership is 16.98%. ImmunityBio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For ImmunityBio (IBRX), the current Institutional Ownership is 16.98% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmunityBio (IBRX) Overvalued in 2026?

Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued. The current stock price of $8.40 is trading 62.6% below its estimated GF Value™ of $22.42. GuruFocus considers ImmunityBio to be Possible Value Trap.

Key valuation signals for IBRX:

  • Institutional Ownership: 16.98%
  • GF Value™: $22.42 vs. price of $8.40 (62.6% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the IBRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmunityBio Business Description

Other Exchanges 26CA:Germany
Address 3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
60GF Score

Get the complete analysis for IBRX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price
$22.42
GF Value